India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Newman Properties, a Massachusetts-based investment firm, has expanded its footprint into Connecticut with the $3.65 million acquisition of a 6,350‑square‑foot retail building in Enfield. Anchored by national restaurant chain Red Robin, the property offers the type of stable tenancy investors seek when entering new markets. The deal underscores growing confidence in anchored retail assets and provides a valuable real-world example for real estate professionals studying market analysis, investment strategy, and portfolio expansion.
JPMorgan now expects national home prices to flatten in 2026, but the Sunbelt is telling a very different story. Florida home values are down 5.1%, Texas is down 2.4%, and analysts warn that years of rapid building are finally catching up to the region. As demand stabilizes and inventory swells, real estate professionals — especially in Florida — face a market full of challenges, opportunities, and critical timing decisions.
Artificial intelligence is finally stepping into the mortgage underwriting spotlight, with 57% of mortgage professionals predicting it will drive the most transformative industry shift in 2026. Thanks to major advancements in language models and workflow automation, AI is now capable of navigating the messy, document-heavy realities that have long slowed underwriting. From faster preapprovals to improved credit analysis and real‑time income verification, AI is streamlining processes while allowing underwriters to focus on true risk management. As regulatory winds shift and grassroots pressure builds within lending teams, the industry is entering a pivotal era where AI‑powered underwriting becomes not just an advantage — but an expectation.
Portland’s top 20 office towers have lost an unprecedented 70% of their value since 2019—plunging from $3 billion to under $1 billion—triggering tax revenue shortfalls, budget crises, and a surge in appeals as the city grapples with its biggest commercial real estate reset in modern history.
South Florida’s luxury real estate market just raised the bar again — this time with a $1 million virtual reality system that lets buyers walk through Dolce & Gabbana’s upcoming Miami tower long before construction wraps. Real estate master’s students were given an immersive look inside the project, discovering how VR is transforming high‑end development, influencing buyer psychology, and shaping the future skills today’s professionals need.
Long Island’s commercial real estate scene is kicking off 2026 with a surge of activity—industrial leases in Medford, neighborhood retail trades in Bohemia, Pizza Hut’s new DELCO expansion in Centereach, mixed‑use acquisitions in Melville, and major investor interest in bank‑leased and franchise-backed properties. From warehouses to restaurant rebrands, these deals highlight a region evolving fast and offering fresh opportunities for agents, investors, and professionals looking to stay ahead in the market.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
